Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study-Reference-Cited by-同舟云学术

Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study

Published:2020-05-14 Issue:7 Volume:36 Page:1117-1124
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Yuan Zhong¹,DeFalco Frank²,Wang Lu¹,Hester Laura¹,Weaver James¹,Swerdel Joel N.¹,Freedman Amy³,Ryan Patrick¹,Schuemie Martijn¹,Qiu Rose⁴,Yee Jacqueline⁴,Meininger Gary⁴,Berlin Jesse A.⁵,Rosenthal Norman⁴

Affiliation:

1. Epidemiology, Janssen Research & Development, LLC, Titusville, NJ, USA;

2. Epidemiology, Janssen Research & Development, LLC, Raritan, NJ, USA;

3. Global Medical Safety, Janssen Research & Development, LLC, Titusville, NJ, USA;

4. Cardiovascular and Metabolism, Janssen Research & Development, LLC, Raritan, NJ, USA;

5. Epidemiology, Johnson & Johnson, Titusville, NJ, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1761312